Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: J Hepatol. 2021 Sep 30;76(2):383–393. doi: 10.1016/j.jhep.2021.09.021

Figure 6. T39 knockdown posttranslationally decreases SCAP in both males and females.

Figure 6.

(A) Hepatic SCAP protein levels of refed male (n=10–11 per group) and (B) female (n=8 per group) Rb1fl/fl mice administered AAV8-GFP or AAV8-TBG-Cre then fed the HFSC diet for 10 weeks. (Top) representative immunoblots and (bottom) quantification, *p<0.05 by two-way ANOVA with Sidak’s multiple comparisons test where column factor is T39 ASO. (C) Immunoblot of SREBP-1 and SCAP protein expression with (D) Quantification of mature SREBP-1 protein, (E) Quantification of SCAP protein and (F) SCAP mRNA levels in Huh-7 cells treated with bortezomib for 3 h in complete media (10% FBS), n=4 per group, *p<0.05, **p<0.01, ***p<0.001 by two-way ANOVA with Tukey’s multiple comparisons test. (G) Co-immunoprecipitation of T39 and VAPB in HEK293A cells expressing WT T39 or T39 containing mutations of the acidic residues of the N-terminus (Δacid). (H) Co-immunoprecipitation of VAPB and SCAP in HeLa cells with/without 1 μM nocodazole.